Dark

Check out our Level2View

PRTG
Portage Biotech Inc. Common Stock
stock NASDAQ

Inactive

Sep 3, 2025

6.81USD-2.155%(-0.15)388,294

Pre-market

0.00USD-100.000%(-6.96)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 11, 2022

10:38AM EST 52 Weeks High And Low Article Benzinga

Jan 5, 2022

08:00AM EST Portage Biotech Inc. (NASDAQ: PRTG) (Portage or the Company), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company will participate in three investor conferences during the month of January. GlobeNewswire Inc

Nov 23, 2021

08:03AM EST Portage Biotech Q2 Net Loss $2.9M Benzinga

08:00AM EST -- Initiated PORT-2 Phase 1/2 IMP-MEL trial in patients with Melanoma & NSCLC -- Enrollment ongoing in Phase 1 PRECIOUS-01 study of PORT-3 for the treatment of NY-ESO-1 positive solid tumors GlobeNewswire Inc

Nov 22, 2021

04:53PM EST Portage Biotech to Present at the Piper Sandler 33rd Annual GlobeNewswire Inc

Nov 15, 2021

11:03AM EST Portage Biotech Highlights Efficacy And Survival Data Presented On Intensity Therapeutics' INT230-6 (PORT-1) At November Scientific Conferences Benzinga

08:00AM EST Portage Biotech Highlights Promising Efficacy and Survival Data GlobeNewswire Inc

Nov 10, 2021

08:01AM EST Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT GlobeNewswire Inc

Sep 21, 2021

10:33AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2021 Benzinga

04:57AM EDT Oppenheimer Initiates Coverage On Portage Biotech with Outperform Rating, Announces Price Target of $30 Benzinga

Sep 10, 2021

08:00AM EDT Portage Biotech Inc. (NASDAQ: PRTG) (Portage or the Company), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that as part of its commitment to investor outreach, management will be participating in the following investor conferences in September 2021. GlobeNewswire Inc

Sep 2, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021 Benzinga

08:29AM EDT B. Riley Securities Initiates Coverage On Portage Biotech with Buy Rating, Announces Price Target of $40 Benzinga

Aug 30, 2021

08:07AM EDT Portage Biotech Q1 EPS $(0.25), Down From $(0.06) YoY Benzinga

08:00AM EDT Portage Biotech Announces Results for First Quarter of 2022 Fiscal GlobeNewswire Inc

Aug 19, 2021

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021 Benzinga

07:33AM EDT Cantor Fitzgerald Initiates Coverage On Portage Biotech with Overweight Rating, Announces Price Target of $35 Benzinga

Aug 12, 2021

08:00AM EDT Portage Biotech Inc., (NASDAQ: PRTG) (Portage or the Company) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today issued the following letter to shareholders: GlobeNewswire Inc

Aug 10, 2021

02:42PM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

Aug 5, 2021

08:38AM EDT Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer Benzinga

Jul 28, 2021

08:00AM EDT - Transformative year included multiple corporate, clinical, and financial milestones, positioning Portage to accelerate development of first-in-class immuno-oncology assets- Additional clinical milestones and company progress anticipated throughout 2H 2021 and 2022 GlobeNewswire Inc

Jul 7, 2021

07:09AM EDT Biohaven Reports Q2 NURTEC ODT Sales of $93M Benzinga

Jun 24, 2021

02:50PM EDT Mid-Afternoon Market Update: Dow Jumps Over 300 Points; Portage Biotech Shares Slide Benzinga

12:52PM EDT Mid-Day Market Update: Rite Aid Falls On Downbeat Sales; Marin Software Shares Gain Benzinga

10:21AM EDT Mid-Morning Market Update: Markets Open Higher; Accenture Reports Upbeat Q3 Results Benzinga

09:13AM EDT Portage Biotech Announces Pricing Of Public Offering Of 1M Ordinary Shares At $23/Share Benzinga

Jun 23, 2021

04:12PM EDT Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares; No Terms Disclosed Benzinga

04:44AM EDT 44 Biggest Movers From Yesterday Benzinga

Jun 18, 2021

07:46AM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

Jun 2, 2021

08:38AM EDT Portage Biotech Highlights Safety And Survival Data From Intensity Therapeutics' IT-01 Study Of INT230-6 At ASCO 2021 Annual Meeting Benzinga

Apr 8, 2021

09:09AM EDT Portage Biotech Doses First Patient In PRECIOUS-01 Study Of PORT-3 For Treatment Of NY-ESO-1 Positive Solid Tumors Benzinga

Share